Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Methods of treating, managing or preventing brain injury are disclosed. Specific methods encompass the administration of EPA and DHA triglycerides for the treatment of brain injuries.

Abstract: A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents.

Abstract: Medicaments and therapeutic compositions comprise a composition (1) comprising at least one polyunsaturated fatty acid, at least one pharmaceutically acceptable derivative of a polyunsaturated fatty acid or mixtures thereof and a composition (2) comprising Red Yeast Rice extract comprising about 0.8 wt. % or more monacolin K. One source of component (1) is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions comprise a composition (1) comprising (A) EPA, pharmaceutically acceptable derivatives of EPA or mixtures thereof, and, optionally, (B) DHA, pharmaceutically acceptable derivatives of DHA or mixtures thereof, wherein the weight ratio of A:B is about 7.5:1 or more, and a composition (2) comprising monacolin K, a source of monacolin K or mixtures thereof. One source of component (1) is fish oil. One source of monacolin K is Red Yeast Rice extract. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions comprise (1) a mixture comprising (A) EPA, pharmaceutically acceptable derivatives of EPA or mixtures thereof, and, optionally, (B) DHA, pharmaceutically acceptable derivatives of DHA or mixtures thereof, wherein the weight ratio of A:B is about 7.5:1 or more, and (2) monacolin K, a source of monacolin K or mixtures thereof. One source of component (1) is fish oil. One source of monacolin K is Red Yeast Rice extract. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions comprise (1) at least one polyunsaturated fatty acid, at least one pharmaceutically acceptable derivative of a polyunsaturated fatty acid or mixtures thereof and (2) Red Yeast Rice extract comprising about 0.8 wt.% or more monacolin K. One source of component (1) is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: Medicaments and therapeutic compositions contain (1) phospholipids having 4,7,10,13,16,19-docosahexaenoic acid covalently bound thereto and (2) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, wherein about 25% of the total 4,7,10,13,16,19-docosahexaenoic acid moieties in the composition are covalently bound to phospholipids, and wherein components (1) and (2) are present in amounts effective to support overall neurological health in a subject.

Abstract: Medicaments and therapeutic compositions contain (1) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, (2) glucosamine sulfate, and (3) undenatured Type II collagen. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for promoting joint health in a subject.

Abstract: Medicaments and therapeutic compositions contain (1) omega-3 polyunsaturated fatty acids and/or derivatives thereof e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof and (2) a probiotic bacteria of the strain Bacillus coagulans. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for support overall immune, digestive and/or cellular health in a subject.

Abstract: Medicaments and therapeutic compositions contain (1) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, (2) undenatured Type II collagen and, optionally, (3) glucosamine sulfate. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for promoting joint health in a subject.

Abstract: An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative of a polyunsaturated fatty acid or mixtures thereof, and (b) an effervescing agent.

Abstract: A therapeutic composition is provided comprising: (1) at least one omega-3 polyunsaturated fatty acid, at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof; (2) resveratrol or a resveratrol derivative; and (3) green tea or a green tea derivative, each in an amount, individually and in combination, effective for a therapeutic, preventive or nutritional activity in a subject in need thereof.

Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.

Abstract: In an aspect of the present invention, a sweetened gelatin capsule comprises a dose and a gelatin capsule encapsulating the dose. The gelatin capsule comprises a gelatin substance, a gelatin softener, water, and a sweetener. The concentration by weight of the water in the gelatin capsule is from about 6% to about 10%. The concentration by weight of the sweetener in the gelatin capsule is from about 0.002% to about 0.003%.